Kemp Law Firm
  • Call Us For A Free Consultation
  • 281.203.0971
Helping You Move Forward - The Woodlands, Texas Family Law & Personal Injury Law Firm Helping You Move Forward - The Woodlands, Texas Family Law & Personal Injury Law Firm Helping You Move Forward - The Woodlands, Texas Family Law & Personal Injury Law Firm Helping You Move Forward - The Woodlands, Texas Family Law & Personal Injury Law Firm

FDA review backs breast cancer drug

WASHINGTON - The Food and Drug Administration has issued a positive review of a breast cancer drug from Roche that could soon become the first pharmaceutical option approved for treating early-stage disease before surgery.

In documents posted online, FDA scientists said women who received the drug Perjeta as initial treatment for breast cancer were more likely to be cancer-free at the time of surgery than women who received older drug combinations. Although the results come from mid-stage trials of the drug, FDA scientists recommended accelerating approval of the drug.

 

That step is reserved for groundbreaking drugs to treat life-threatening diseases. Roche's Genentech unit is now seeking approval to use the drug at a much earlier stage of the disease: after diagnosis and before surgery to remove the tumor.

If approved, Perjeta would be the first cancer drug approved for use as a pre-surgical step.

The FDA is scheduled to make a decision on whether to approve Perjeta for early-stage breast cancer by Oct. 31.

Source: Chron.com

Post a Comment

Your email is never published nor shared. Required fields are marked *

*
*

Archives

Categories

  • This field is for validation purposes and should be left unchanged.